Entities / Company
Immuneering (United States).
company in Cambridge, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 13
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Immuneering received a patent grant for a pancreatic cancer drug.Speculative1 report
-
Immuneering, Regeneron Pharmaceuticals, and Eli Lilly signed agreements regarding clinical trials and supply for specific drugs.Some support1 report
-
Immuneering (United States) appointed Leerink partners as a financial advisor for a private placement, effective August 27, 2025.Some support1 report
-
Thomas Schall purchased shares of Immuneering on September 5, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Immuneering (United States) this week
News at the entities that move Immuneering (United States) most-
Regeneron Pharmaceuticals TransactionalMorgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron Pharmaceuticals stock.Moves Immuneering (United States)
-
Cambridge Shared contextAn event featuring historical scientific instruments was held in Cambridge, MA, involving professor Evelynn Hammonds.Moves Immuneering (United States)
Connections
The 3 strongest of 13, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Igor Matushansky Structural
Igor Matushansky serves as the Chief Medical Officer for Immuneering.
-
Regeneron Pharmaceuticals Transactional
Immuneering provides clinical trial and supply agreements for its compounds to Regeneron Pharmaceuticals.
-
Cambridge Shared context
Immuneering is located and based in Cambridge, Massachusetts.
History
Events by the month they beganJune 2026
5 events- Immuneering submitted a meeting request to the FDA regarding its therapies.
- Immuneering received a patent grant for a pancreatic cancer drug.
- Immuneering, Regeneron Pharmaceuticals, and Eli Lilly signed agreements regarding clinical trials and supply for specific drugs.
- Immuneering (United States) appointed Leerink partners as a financial advisor for a private placement, effective August 27, 2025.
- Thomas Schall purchased shares of Immuneering on September 5, 2025.